Overview

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.